Curocellbtx

Market position

RIMQARTO is described as South Korea's first domestically developed and commercialized CAR T-cell therapy and the country's 42nd domestically developed new drug, positioning Curocell as an early domestic entrant in the Korean CAR-T and advanced-therapy market.

Unlike conventional CD19 CAR-T products, CRC01/RIMQARTO incorporates the OVIS platform's simultaneous downregulation of PD-1 and TIGIT signaling. The company also secured full rather than conditional regulatory approval, with the MFDS waiving Phase 3 data requirements.

Technology

Curocell's OVIS (Overcome Immune Suppression) platform is a first-in-class CAR-T approach that suppresses expression of the immune checkpoint receptors PD-1 and TIGIT on engineered T cells, intended to overcome ligand-mediated immune suppression in the tumor microenvironment and improve cytotoxicity, persistence and resistance to T-cell exhaustion relative to conventional CAR-T constructs. The lead construct, CRC01, targets CD19 and is manufactured as an autologous, lentivirally engineered product; the company also cites work on in vivo CAR-T approaches. Its Daejeon CAR-T Center combines commercial-scale GMP manufacturing with R&D for pipeline development.

Go-to-market

Following MFDS approval, Curocell is working toward patient access in Korea, including national health insurance reimbursement listing via the Ministry of Health and Welfare's concurrent pilot program for approval, evaluation and negotiation. Internationally, the company states it is targeting global market entry with a focus on North America and Europe, and it has announced a partnership with Türkiye's Biruni Group for joint development and local market entry of RIMQARTO (림카토).

Adult patients with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma who have received two or more prior lines of systemic therapy, treated at hospitals administering CAR T-cell therapy; future pipeline targets patients with solid tumors and autoimmune diseases.

Geography

Headquartered in Daejeon, South Korea (11 Gukjegwahak 16-ro, Yuseong-gu, Daejeon 34002), with a CAR-T Center including GMP manufacturing and R&D in the Daejeon International Science & Business Belt. Global development and commercialization efforts focus on North America and Europe, and a partnership with the Biruni Group addresses Türkiye.

History

Curocell was described in December 2021 as a clinical-stage biotech based in Daejeon, South Korea, then conducting a Phase 1 trial of CRC01 (anbalcabtagene autoleucel), with a Phase 2 trial planned to start in Korea in the first half of 2022. That month it broke ground on a CAR-T Center in Daejeon housing a commercial GMP manufacturing facility and an R&D center. Phase 1/2 and pivotal Phase 2 data subsequently supported a biologics license application; although the filing was initially submitted for conditional approval, the MFDS waived the Phase 3 data requirement given the third-line lymphoma setting and the novelty of the therapy. Full approval followed on 29 April 2026, and the program moved into commercial manufacturing, announced in May 2026 together with CDMO partner ProBio.

Risks & controversies

The MFDS approval is subject to long-term follow-up studies and risk management plans monitoring safety and efficacy, consistent with other global CAR T-cell therapies. Reported grade 3/4 adverse events in clinical studies included neutropenia, anemia and thrombocytopenia, alongside cytokine release syndrome and neurotoxicity events. Development and approval depended in part on Korean government R&D funding and expedited review programs, and commercial manufacturing depends on external CDMO supply of lentiviral vectors.